Public Health Observatory of New Zealand Inc Te Rōpū Mātai Hauora Pāpo O Aotearoa Public Health Observatory of NZ Te Ropu Matai Hauora Papori O Aotearoa 2024 Virtual Conference

# A Robust Machine Learning Model for Long-Term Survival Prediction of Breast Cancer Patients in New Zealand

Rooshan Ghous & Binh Thanh Dang

School of Information Technology

WhiteCliffe College, Auckland, New Zealand



Te Réhita Mate Ütaetae Breast Cancer Foundation National Register

## Agenda

- Motivation
- Research Objectives
- Pilot Study US SEER Dataset
- NZ Breast Cancer Dataset
- The Proposed Approach
- Preliminary Results and Discussion

#### **Motivation**

• Breast cancer is the most commonly affecting cancer in women & the third most prevalent cancer overall in NZ, resulting in a toll of 600 fatalities annually (MOH, 2023).

• A robust survival prediction model can help improve long term disease outcome in New Zealand by understanding its prognosis and targeting the risk factors.

#### **Case Study**



The Breast Cancer Research Foundation 16,198 followers 3mo • 🚯

Olivia Munn spoke out about her breast cancer diagnosis and gave a shoutout to the Tyrer-Cuzick risk assessment model developed by Dr. Jack Cuzick, a BCRF investigator since 2011. The test and score is widely used to help identify people at higher-than-average risk of breast cancer.

#### https://bit.ly/3UlyjUK



Olivia Munn's 'Terrifying' Breast Cancer Diagnosis After Baby Joy: 4 Surgeries in 10 Months, and Medically...

people.com

\*\*\*

# Why Develop a Local Survival Prediction Tool

Artificial Intelligence (AI) based tools for survival risk prediction are sensitive to training data and therefore need for a local prediction model.

- Help identify survival time precisely based on individual risk
- Selecting favorable treatment plan & targeting modifiable risk factors
- Triage for treatment & screening
- Assist in public health policymaking
- Reducing the ethnic disparity that exists in health outcomes of cancer patients

#### **Research Objectives**

- 1. Develop a robust 15-year survival prediction model for breast cancer using machine learning.
- 2. Identify temporal variations that may exist within risk factors during 5-year, 10-year & 15 years period post diagnosis.

# Pilot Study: Surveillance, Epidemiology & End Result (SEER)Data

US Surveillance Epidemiology & End Result Data

Patients diagnosed between 1/1/2010 -31/12/2014

Total Number of Cases	289,303	
Gender	Female	289,303
Cancer at Diagnosis	Localized to breast	271,763
	Distant Metastasis	17,540
Patient Status at 60 months	Alive	211,727
	Deceased	77,576

Comparison of ML Model Performance on SEER Data			
Model Name	Area Under Curve (AUC)		
Logistic Regression	0.8233		
Decision Tree Classifier	0.6218		
Random Forest Classifier	0.8000		
XG Boost	<mark>0.8258</mark>		
Deep Neural Network	0.8225		

[Range for AUC 0-1]

Comparison c	of ML Mod	el Performa	nce on SE	ER Data
Model Name	Accuracy	Precision	Recall	F-1 Score
Logistic Regression	87.18%	88.60%	97.56%	92.86%
Decision Tree Classifier	86.61%	87.19%	<mark>98.85%</mark>	92.66%
Random Forest Classifier	86.65%	88.40%	97.11%	92.55%
XG Boost	<mark>87.37%</mark>	<mark>88.89%</mark>	97.39%	92.95%
K- Nearest Neighbor	85.68%	87.99%	96.40%	92.01%
Deep Neural Network	87.22%	87.80%	98.76%	<mark>92.96%</mark>

#### NZ Breast Cancer Dataset



Data acquired from New Zealand Breast Cancer Foundation National Register

#### Inclusion criteria: Women registered between 01/01/2002 – 31/12/2017


**Exclusion criteria:** Patients lost to follow-up, and those with metastasis at diagnosis


Cohort ID	Inclusion Period	Follow-up Period
Cohort 1	All patients diagnosed in 2002-2007	Followed up for 180 months to estimate 15-year survival
Cohort 2	All patients diagnosed in 2008-2012	Followed up for 120 months to estimate 10-year survival
Cohort 3	All patients diagnosed in 2013-2017	Followed up for 60 months to estimate 5-year survival

### **Dataset Summary**


Te Rehita Mate Utaetae - Breast Cancer Foundation National Register			
Total Number of Cases		26,786	
Gender	Female	26,594	
	Male	186	
	Unknown	5	
	Birth sex female	1	
Cancer at Diagnosis	Localized to breast	22,443	
	Distant Metastasis	4,124	
	Unknown	27	
Total Cases		22,470	

About 230 predictor variables and 65 variables related to outcome and follow-up were requested for analysis





#### Distribution of Diagnosis Age by Ethnicity



#### **Multifactor Risk Model**


Significant predictors of breast cancer survival across 7 fields including

- 1. Patient demographics
- 2. Clinical presentation and radiological features
- 3. Histological features including biomarkers
- 4. Stage & grade of tumor
- 5. Tumor characteristics including hormone receptor status
- 6. Treatment received
- 7. Histopathological details

### **Feature Ranking Using XGBoost**

- XGBoost aids in variable selection, to help select most significant predictors of survival in breast cancer patients. It has ability to integrate diverse clinical data types and analyze it to rate features by importance
- XGBoost is a robust modelling algorithm due to its ability to avoid overfitting and its ability to handle complex relationships in data, making it suitable for identifying important features in survival analysis
- Its tree-based structure allows it to capture nonlinear relationships between features and survival outcomes, which traditional linear models may struggle to capture non-linear relationships effectively- critical to understand cancer prognosis

#### Feature ranking of risk factors for 5-year survival using XG Boost



### **Results**

The risk factors show temporal variation over time. This can be significant for accurate model development & later in treatment planning.

The Machine learning models are highly sensitive to data selected. Therefore, a population specific tool is critical for accurate prediction that includes relevant risk factors & representative population.

#### Conclusion

Cancer is a complex disease with multiple factors affecting its outcome. Understanding their role in the prognosis is complex and critical task, especially in the long term.

Al can help decipher these relationships by use of good data and team of multidisciplinary experts.

#### **Clinical Advisors**

Clinical Advisor: Dr. Reuben Broom Clinical Researcher & Oncologist

> Dr. Vanessa Blair Breast Surgeon & Researcher

Maori Integrity Advisor:

George Tongariro

Cultural Capacity & Capability Building for Indigenous Peoples (Māori & Pasifika)

#### Acknowledgements

We extend our gratitude to the Te Rēhita Mate Ūtaetae - Breast Cancer Foundation National Register for providing us with data funded by the New Zealand Breast Cancer Foundation NZ.

Special thanks to Jane Yates (Data Manager for the Northern Region) and the dedicated Data Managers at BCFNR for their ongoing support.

We sincerely appreciate the invaluable guidance from our Clinical Advisors.

Special thanks to George Tongariro for his input in our project, ensuring it aligns with principles of Maori and Pacifica sovereignty.

# Thank you

Rooshan Ghous: Email: <u>20231512@mywhitecliffe.com</u>